The trading price of Caladrius Biosciences, Inc. (NASDAQ:CLBS) closed lower on Monday, Feb 22, closing at $2.29, -2.62% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $2.1700 and $2.3593. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 1.23. In examining the 52-week price action we see that the stock hit a 52-week high of $4.89 and a 52-week low of $1.05. Over the past month, the stock has suffered -10.8% in value.
Caladrius Biosciences, Inc., whose market valuation is $124.66 Million at the time of this writing, is expected to release its quarterly earnings report on February 25, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.25 per share this quarter, however they have predicted annual earnings per share of -$0.81 for 2021 and -$0.48 for 2022. It means analysts are expecting annual earnings per share growth of -0.57% this year and -0.41% next year.
On the technical side, indicators suggest CLBS has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CLBS a recommendation rating is 2. Out of them, 1 rate it a Hold, while 1 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged Caladrius Biosciences, Inc. (CLBS) as Underperform, while not any of them advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that CLBs price is currently -1.5% off the SMA20 and 19.24% off the SMA50. The RSI metric on the 14-day chart is currently showing 51.99, and weekly volatility stands at 9.91%. When measured over the past 30 days, the indicator reaches 11.55%. Caladrius Biosciences, Inc. (NASDAQ:CLBS)’s beta value is currently sitting at 1.23, while the Average True Range indicator is currently displaying 0.35. With analysts defining $14-$14 as the low and high price targets, we arrive at a consensus price target of $14 for the trailing 12-month period. The current price is about 527.8% off the estimated low and 527.8% off the forecast high, based on this estimate. Investors will be thrilled if CLBs share price rises to $14, which is the median consensus price. At that level, CLBs share price would be +527.8% above current price.
To see how Caladrius Biosciences, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: CLBS stock’s performance was -2.62% in the latest trading, and -28.75% in the past year, while Bristol-Myers Squibb Company (BMY) has traded +0.64% on the day and positioned -7.07% lower than it was a year ago. Another comparable company Amgen Inc (AMGN) saw its stock close -0.09% lower in the most recent trading session but was up +3.9% in a year. Furthermore, Gilead Sciences Inc (GILD) showed a decline of -2.62% on the day while its price kept declining at -28.75% over the past year. Caladrius Biosciences, Inc. has a P/E ratio of 0, compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 18.8. Also in last trading session, the S&P 500 Index has soared -0.77%, while the Dow Jones Industrial also saw a positive session, up +0.09% on the day.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
An evaluation of the daily trading volume of Caladrius Biosciences, Inc. (NASDAQ:CLBS) indicates that the 3-month average is 4.84 Million. However, this figure has declined over the past 10 days to an average of 12.41 Million.
Currently, records show that 32.97 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 12.18% of outstanding shares, whereas institutions hold 19.23%. The stats also highlight that short interest as of January 28, 2021, stood at 2.93 Million shares, resulting in a short ratio of 0.42 at that time. From this, we can conclude that short interest is 8.88% of the company’s total outstanding shares. It is noteworthy that short shares in January were down slightly from the previous month’s figure, which was 144.67 Million. However, since the stock’s price has seen +55.94% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.